Multiple research collaborations have been formed with MSKCC with focuses in kidney cancer, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL).

MSKCC provided CGI with a multitude of lymphoma specimens of varying histologies with known clinical outcomes for the and clinical validations of MatBA® for CLL, DLBCL, MCL and FL. CGI also received cores of FFPE tumor material spear-heading and providing justification for the use of this tissue type in array-CGH.

A biological material transfer agreement allowed the evaluation the first application of CGI’s proprietary array-CGH product line, UroGenRA™, in the diagnosis and subtyping of renal mass aspirates/core biopsies. The specimens were also used to compare UroGenRA™ with routine pathology testing.